Payment overview · 2025
General Payments
$302.30
11 reported records · 10 companies
Healthcare provider profile · identity verified
Mohamed E Eldaly, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · TURLOCK, CA · NPI 1962501718
Verified facts
What the public records show
CMS Open Payments records show Mohamed E Eldaly, M.D. received $302.30 in general payments during 2025 across 11 reported records.
Aveo Pharmaceuticals, Inc. accounted for 29.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Calquence.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xtandi as an associated drug or biological on 11345 records involving 5418 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Xtandi by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CALQUENCE as an associated drug or biological on 8404 records involving 3935 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Calquence by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TAGRISSO as an associated drug or biological on 5285 records involving 2776 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Tagrisso by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Eliquis by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported POMALYST as an associated drug or biological on 282 records involving 237 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Pomalyst by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Aveo Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $89.99 | 29.8% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $44.03 | 14.6% | 2 | 2025 |
| SERVIER PHARMACEUTICALS LLC | Unresolved — no canonical attribution shown | $29.64 | 9.8% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $28.47 | 9.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.30 | 6.7% | 1 | 2025 |
| Deciphera Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.88 | 6.6% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $19.36 | 6.4% | 1 | 2025 |
| BeiGene USA, Inc. | Unresolved — no canonical attribution shown | $18.47 | 6.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.45 | 6.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.71 | 4.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $212.31 | 10 |
| Education | $89.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FOTIVDA Normalized: fotivda |
Drug | Aveo Pharmaceuticals, Inc. | $89.99 | 1 | 2025 |
Source payment records
|
|||||
| Voranigo Normalized: voranigo |
Drug | SERVIER PHARMACEUTICALS LLC | $29.64 | 1 | 2025 |
Source payment records
|
|||||
| Vyloy Normalized: vyloy |
Drug | Astellas Pharma US Inc | $28.47 | 1 | 2025 |
Source payment records
|
|||||
| Enhertu Normalized: enhertu |
Drug | Daiichi Sankyo Inc. | $26.36 | 1 | 2025 |
Source payment records
|
|||||
| CALQUENCE Normalized: calquence |
Drug | AstraZeneca Pharmaceuticals LP | $20.30 | 1 | 2025 |
Source payment records
|
|||||
| QINLOCK Normalized: qinlock |
Drug | Deciphera Pharmaceuticals Inc. | $19.88 | 1 | 2025 |
Source payment records
|
|||||
| ROMVIMZA Normalized: romvimza |
Drug | Deciphera Pharmaceuticals Inc. | $19.88 | 1 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation | $19.36 | 1 | 2025 |
Source payment records
|
|||||
| BRUKINSA Normalized: brukinsa |
Drug | BeiGene USA, Inc. | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| DATROWAY Normalized: datroway |
Drug | Daiichi Sankyo Inc. | $17.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CALQUENCE calquence |
2025 | Calquence | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Xtandi open payments reported associated product |
CMS Open Payments — General Payments 11345 supporting records · 5418 recipient NPIs · example record 1238560686 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
96 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | CALQUENCE open payments reported associated product |
CMS Open Payments — General Payments 8404 supporting records · 3935 recipient NPIs · example record 1206131382 |
Calquence · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TAGRISSO open payments reported associated product |
CMS Open Payments — General Payments 5285 supporting records · 2776 recipient NPIs · example record 1206131546 |
Tagrisso · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
60 | 18 |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | POMALYST open payments reported associated product |
CMS Open Payments — General Payments 282 supporting records · 237 recipient NPIs · example record 1184378437 |
Pomalyst · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Anastrozole | Anastrozole | 502 | 102 |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 295 | 79 |
| Ondansetron Odt | Ondansetron | 219 | 133 |
| Pantoprazole Sodium | Pantoprazole Sodium | 216 | 58 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 188 | 120 |
| Gabapentin | Gabapentin | 168 | 42 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 141 | 48 |
| Raloxifene Hcl | Raloxifene Hcl | 117 | 28 |
| Imbruvica | Ibrutinib | 101 | 12 |
| Levofloxacin | Levofloxacin | 99 | 69 |
| Xtandi | Enzalutamide | 96 | 13 |
| Megestrol Acetate | Megestrol Acetate | 94 | 33 |
| Azithromycin | Azithromycin | 74 | 51 |
| Letrozole | Letrozole | 74 | 16 |
| Prednisone | Prednisone | 67 | 19 |
| Bicalutamide | Bicalutamide | 61 | 17 |
| Olanzapine Odt | Olanzapine | 61 | 21 |
| Eliquis | Apixaban | 60 | 18 |
| Levothyroxine Sodium | Levothyroxine Sodium | 50 | 16 |
| Tramadol Hcl | Tramadol Hcl | 49 | 28 |
| Abiraterone Acetate | Abiraterone Acetate | 46 | suppressed |
| Potassium Chloride | Potassium Chloride | 43 | 15 |
| Jakafi | Ruxolitinib Phosphate | 42 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | suppressed |
| Cephalexin | Cephalexin | 40 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 39 | suppressed |
| Ibrance | Palbociclib | 35 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 34 | 12 |
| Montelukast Sodium | Montelukast Sodium | 34 | suppressed |
| Furosemide | Furosemide | 33 | 15 |
| Alendronate Sodium | Alendronate Sodium | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 32 | 12 |
| Trazodone Hcl | Trazodone Hcl | 32 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | suppressed |
| Dexamethasone | Dexamethasone | 31 | 14 |
| Hydroxyurea | Hydroxyurea | 31 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 31 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 30 | suppressed |
| Lorazepam | Lorazepam | 30 | 16 |
| Calquence | Acalabrutinib Maleate | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 13 |
| Allopurinol | Allopurinol | 26 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 26 | 20 |
| Exemestane | Exemestane | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Folic Acid | Folic Acid | 23 | suppressed |
| Imatinib Mesylate | Imatinib Mesylate | 23 | suppressed |
| Omeprazole | Omeprazole | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 22 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 22 | suppressed |
| Cabometyx | Cabozantinib S-Malate | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 18 |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Losartan Potassium | Losartan Potassium | 19 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 18 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 18 | suppressed |
| Lenalidomide | Lenalidomide | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 16 | 15 |
| Pomalyst | Pomalidomide | 16 | suppressed |
| Revlimid | Lenalidomide | 16 | suppressed |
| Tagrisso | Osimertinib Mesylate | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Meloxicam | Meloxicam | 15 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 14 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 14 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Hizentra | Immun Glob G(Igg)/Pro/Iga 0-50 | 12 | suppressed |
| Lumakras | Sotorasib | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Pazopanib Hcl | Pazopanib Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $302.30 · 11 records | Aveo Pharmaceuticals, Inc. | BRUKINSA, CALQUENCE, DATROWAY, Enhertu, FOTIVDA, Fabhalta, QINLOCK, REBLOZYL, ROMVIMZA, Voranigo, Vyloy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Calquence play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error